Beximco Faces Potentially Rough Ride In The Face Of Macroeconomic Headwinds
Revenue Grows But Profits Take A Hit At Bangladeshi Generics Firm
Following a year of impressive business developments, economic developments such as a depreciating local currency threaten to knock Beximco off-course.
You may also be interested in...
Bangladesh-based Beximco has delivered double-digit growth in its financial first half ended 31 December 2021, on the back of 20 new product launches domestically and expanding into new markets internationally.
Beximco has completed its acquisition of a majority stake in Sanofi Bangladesh to “expand its core capabilities and product offerings.” With its second major acquisition under its belt, Beximco said that it plans to continue its diversification and expansion.
After nearly two difficult years for Nichi-Iko Pharmaceutical, the firm has announced at it will be acquired by a private equity fund and delisted from the Toyko Stock Exchange in 2023 and its CEO will step down from his post.